Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 272

1.

Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population.

Shaya FT, Blume SW, Blanchette CM, Weir MR, Mullins CD.

Arch Intern Med. 2005 Jan 24;165(2):181-6.

PMID:
15668364
2.
3.

Current perspective on the cardiovascular effects of coxibs.

Konstam MA, Weir MR.

Cleve Clin J Med. 2002;69 Suppl 1:SI47-52. Review.

PMID:
12086293
4.

Underutilization of preventive strategies in patients receiving NSAIDs.

Sturkenboom MC, Burke TA, Dieleman JP, Tangelder MJ, Lee F, Goldstein JL.

Rheumatology (Oxford). 2003 Nov;42 Suppl 3:iii23-31.

PMID:
14585915
6.

Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.

Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S.

Arthritis Rheum. 2006 May;54(5):1378-89.

7.

Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors.

Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A.

Arch Intern Med. 2005 Jan 24;165(2):189-92.

PMID:
15668365
8.

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.

Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A.

Arch Intern Med. 2003 Feb 24;163(4):481-6.

PMID:
12588209
9.

Modeling risk of gastrointestinal events among Medicaid NSAID users using propensity scores.

Shaya FT, Samant N, Skolasky R, Saunders E.

Expert Rev Pharmacoecon Outcomes Res. 2005 Oct;5(5):625-32. doi: 10.1586/14737167.5.5.625.

PMID:
19807588
10.
12.

"Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs.

Bennett K, Teeling M, Feely J.

Eur J Clin Pharmacol. 2003 Nov;59(8-9):645-9. Epub 2003 Aug 27.

PMID:
12942226
14.

Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.

Moride Y, Ducruet T, Boivin JF, Moore N, Perreault S, Zhao S.

Arthritis Res Ther. 2005;7(2):R333-42. Epub 2005 Jan 17.

15.

Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke.

Haag MD, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH.

Arch Intern Med. 2008 Jun 9;168(11):1219-24. doi: 10.1001/archinte.168.11.1219.

PMID:
18541831
16.

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.

Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL.

Ann Intern Med. 2005 Feb 1;142(3):157-64.

PMID:
15684203
17.

Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.

White WB, Faich G, Borer JS, Makuch RW.

Am J Cardiol. 2003 Aug 15;92(4):411-8.

PMID:
12914871
18.

Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.

Rostom A, Dubé C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D; U.S. Preventive Services Task Force..

Ann Intern Med. 2007 Mar 6;146(5):376-89. Review.

PMID:
17339623
20.

A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.

Price-Forbes AN, Callaghan R, Allen ME, Rowe IF.

Rheumatology (Oxford). 2005 Jul;44(7):921-4. Epub 2005 Apr 12.

PMID:
15827035

Supplemental Content

Support Center